Mogamulizumab (Poteligeo)
Class: Monoclonal antibody that binds to a protein (CC chemokine receptor type 4).
Disease: Relapsed or refractory mycosis fungoides or Sézary syndrome.
Dose: Intravenous infusion 1 mg/kg.
AE: Dermatologic toxicity.
MAVORIC trial (NCT01728805): Patients who received mogamulizumab had improved progression-free survival (median 7.7 months), compared with those taking vorinostat (median 3.1 months).
Moxetumomab pasudotox-tdfk (Lumoxiti)
Class: CD22-directed cytotoxin fused with a fragment of Pseudomonas exotoxin A.
Disease: Relapsed or refractory hairy cell leukemia previously treated with at least two prior systemic therapies, including a purine nucleoside analogue.
Dose: Intravenously as 0.04 mg/kg.
AE: Hemolytic uremic syndrome.
1053 trial (NCT01829711): 30% of the patients who received moxetumomab pasudotox-tdfk had a durable complete response confirmed by maintenance hematologic remission.
Talazoparib (Talzenna)
Class: Poly (ADP-ribose) polymerase (PARP) inhibitor.
Disease: gBRCAm HER2-negative locally advanced or metastatic breast cancer.
Dose: 1 mg orally per day.
EMBRACA trial (NCT01945775): Patients who received talazoparib demonstrated significantly longer progression-free survival, with a median of 8.6 months versis 5.6 months in the control arm.
Dr. Bryer is a resident in the department of internal medicine at the University of Pennsylvania, Philadelphia. Dr. Mentzer is chief of hematology-oncology at Pennsylvania Hospital and professor of medicine at the University of Pennsylvania. Dr. Henry is a hematologist-oncologist at Pennsylvania Hospital and a professor of medicine at the University of Pennsylvania.